次世代婦人科がん診断市場：コンポーネント、技術、適応症、エンドユーザー別-2025～2030年の世界予測

次世代婦人科がん診断市場は、2023年に21億3,000万米ドルと評価され、2024年には23億2,000万米ドルに達すると予測され、CAGR 10.49％で成長し、2030年には42億9,000万米ドルに達すると予測されています。

次世代婦人科がん診断市場には、子宮頸がん、卵巣がん、子宮内膜がんなどのがんを、より早期で治療可能な段階で発見するための先進的な技術や方法が含まれています。がん罹患率の上昇、意識の高まり、個別化医療への需要によって必要性が高まる中、これらの診断は従来の方法よりも精度と効率を向上させ、最終的に患者の転帰を改善する上で極めて重要です。用途はスクリーニング、診断、モニタリングに及び、主要エンドユーザーは病院、診断ラボ、研究機関などです。市場の勢いは、分子診断の技術的進歩、データ分析のための人工知能（AI）の統合、迅速な製品開発と承認を促進する規制状況の支援によって大きく影響を受けています。特に医療インフラへのアクセスが限られている未開拓地域におけるポイントオブケア検査の拡大やリキッドバイオプシー技術の強化にビジネス機会があります。しかし、市場は、先進的診断ツールの高額なコスト、適切な償還施策の欠如、発展途上国における認知度とアクセシビリティを阻害する社会文化的障壁などの課題に直面しています。こうした障害にもかかわらず、技術革新と研究は、費用対効果の高いソリューション開発、感度と特異度の向上、遠隔診断を可能にする遠隔医療プラットフォームの進歩に焦点を当てるべきです。次世代シーケンサー（NGS）、バイオマーカー探索、AIアプリケーションを活用したプラットフォームは、市場参入者にとって特に有望です。医療プロバイダーとの戦略的提携や学術機関との連携はイノベーションを加速させ、デジタルヘルスに対する受容の高まりは市場拡大をさらに刺激します。医療施策の調整と研究開発への投資拡大は既存の限界を緩和する可能性があるが、市場の潜在力を獲得するには、技術の進歩に積極的に適応し、世界の医療アクセスの格差に対処する必要があります。市場は基本的に引き続きダイナミックであり、企業は婦人科医療における次世代診断技術の大きな可能性を活用するために、機敏かつ先進的なアプローチを維持する必要があります。

市場力学：急速に進化する次世代婦人科がん診断市場の主要市場洞察を公開

次世代婦人科がん診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 次世代婦人科がん患者の増加
  • 疾患の早期診断と治療への傾斜
  • 新規マーカーと遺伝子マーカーの活用
• 市場抑制要因
  • 次世代婦人科がん診断に関連する高コスト
• 市場機会
  • 遠隔医療と遠隔モニタリングの新たな動向
  • 検診プログラムと医療ツーリズムの増加
• 市場課題
  • 次世代婦人科がん診断検査の製造の複雑さ

ポーターのファイブフォース：次世代婦人科がん診断市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：次世代婦人科がん診断市場における外部からの影響の把握

外部マクロ環境要因は、次世代婦人科がん診断市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：次世代婦人科がん診断市場における競合情勢の把握

次世代婦人科がん診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：次世代婦人科がん診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、次世代婦人科がん診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：次世代婦人科がん診断市場における成功への道筋を描く

次世代婦人科がん診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 次世代婦人科がんの発生率上昇
    • 病気の早期診断と治療への傾向
    • 新規マーカーと遺伝子マーカーの活用
  • 抑制要因
    • 次世代婦人科がん診断に伴う高コスト
  • 機会
    • 遠隔医療と遠隔モニタリングの新たな動向
    • 検査プログラムと医療ツーリズムの増加
  • 課題
    • 次世代婦人科がん診断検査の製造における複雑さ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 次世代婦人科がん診断市場：コンポーネント別

• イントロダクション
• 消耗品
• 機器
• ソフトウェア

第7章 次世代婦人科がん診断市場：技術別

• イントロダクション
• 次世代シーケンシング（NGS）
• ポリメラーゼ連鎖反応（PCR）

第8章 次世代婦人科がん診断市場：適応症別

• イントロダクション
• 子宮頸がん
• 卵巣がん
• 子宮がん

第9章 次世代婦人科がん診断市場：エンドユーザー別

• イントロダクション
• 学術研究機関
• 診断ラボ
• 病院と外来センター

第10章 南北アメリカの次世代婦人科がん診断市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の次世代婦人科がん診断市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの次世代婦人科がん診断市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Agilent Technologies, Inc.
• ARUP Laboratories
• Becton, Dickinson and Company
• BGI Genomics Co., Ltd.
• Bio-Rad Laboratories, Inc.
• Centogene N.V.
• Danaher Corporation
• Epic Sciences Inc.
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fujifilm Holdings Corporation
• Fulgent Genetics, Inc.
• GE HealthCare Technologies, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Interpace Diagnostics, LLC
• Janssen Pharmaceuticals, Inc.
• Konica Minolta, Inc.
• Koninklijke Philips N.V.
• Lucence Diagnostics Pte Ltd
• Medtronic plc
• Merck KGaA
• Myriad Genetics, Inc.
• Natera, Inc.
• Novartis AG
• QIAGEN N.V.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 36. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 37. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 58. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 62. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 63. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 131. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 147. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 148. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 151. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 152. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 191. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Next-Generation Gynecological Cancer Diagnostics Market was valued at USD 2.13 billion in 2023, expected to reach USD 2.32 billion in 2024, and is projected to grow at a CAGR of 10.49%, to USD 4.29 billion by 2030.

The next-generation gynecological cancer diagnostics market encompasses advanced technologies and methods for detecting cancers such as cervical, ovarian, and endometrial at earlier and more treatable stages. With increased necessity driven by rising cancer prevalence, heightened awareness, and demand for personalized medicine, these diagnostics are pivotal in offering improved accuracy and efficiency over traditional methods, ultimately enhancing patient outcomes. Applications span screening, diagnostics, and monitoring, with major end-users including hospitals, diagnostic labs, and research institutions. The market's momentum is significantly influenced by technological advancements in molecular diagnostics, the integration of artificial intelligence (AI) for data analysis, and supportive regulatory landscapes, fostering expedited product development and approvals. Opportunities lie in expanding point-of-care testing and enhancing liquid biopsy techniques, particularly in underserved regions with limited access to healthcare infrastructure. However, the market faces challenges such as high costs of advanced diagnostic tools, a lack of adequate reimbursement policies, and socio-cultural barriers hindering awareness and accessibility in developing countries. Despite these obstacles, innovation and research should focus on cost-effective solution development, increasing sensitivity and specificity, and advancing telehealth platforms to enable remote diagnostics. Platforms leveraging next-gen sequencing (NGS), biomarker discovery, and AI applications are particularly promising for market entrants. Strategic partnerships with healthcare providers and academic collaborations can accelerate innovation, with the growing acceptance of digital health further stimulating market expansion. While healthcare policy adjustments and increased investment in R&D could mitigate existing limitations, capturing market potential requires proactive adaptation to technological advancements and addressing disparities in healthcare access globally. The market remains fundamentally dynamic, requiring businesses to remain agile and forward-thinking in their approach to tap into the vast potential of next-generation diagnostic technologies in gynecological healthcare.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Next-Generation Gynecological Cancer Diagnostics Market

The Next-Generation Gynecological Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of next-generation gynecological cancer cases
  • Inclination towards early diagnosis and treatment of diseases
  • Utilization of novel markers and genetic markers
• Market Restraints
  • High cost associated with next generation gynecological cancer diagnostics
• Market Opportunities
  • Emerging trend of telemedicine and remote monitoring
  • Growing number of screening programs and medical tourism
• Market Challenges
  • Complexity in manufacturing of next generation gynecological cancer diagnostics tests

Porter's Five Forces: A Strategic Tool for Navigating the Next-Generation Gynecological Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Next-Generation Gynecological Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Next-Generation Gynecological Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Next-Generation Gynecological Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Next-Generation Gynecological Cancer Diagnostics Market

A detailed market share analysis in the Next-Generation Gynecological Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Next-Generation Gynecological Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Next-Generation Gynecological Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Next-Generation Gynecological Cancer Diagnostics Market

A strategic analysis of the Next-Generation Gynecological Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Gynecological Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, Becton, Dickinson and Company, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Fulgent Genetics, Inc., GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Interpace Diagnostics, LLC, Janssen Pharmaceuticals, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Lucence Diagnostics Pte Ltd, Medtronic plc, Merck KGaA, Myriad Genetics, Inc., Natera, Inc., Novartis AG, QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Gynecological Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Components, market is studied across Consumables, Instruments, and Software.
• Based on Technology, market is studied across Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR).
• Based on Indication, market is studied across Cervical Cancer, Ovarian Cancer, and Uterine Cancer.
• Based on End User, market is studied across Academic & Research Institutes, Diagnostic Laboratories, and Hospitals & Ambulatory Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of next-generation gynecological cancer cases
    • 5.1.1.2. Inclination towards early diagnosis and treatment of diseases
    • 5.1.1.3. Utilization of novel markers and genetic markers
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with next generation gynecological cancer diagnostics
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging trend of telemedicine and remote monitoring
    • 5.1.3.2. Growing number of screening programs and medical tourism
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity in manufacturing of next generation gynecological cancer diagnostics tests
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Next-Generation Gynecological Cancer Diagnostics Market, by Components

• 6.1. Introduction
• 6.2. Consumables
• 6.3. Instruments
• 6.4. Software

7. Next-Generation Gynecological Cancer Diagnostics Market, by Technology

• 7.1. Introduction
• 7.2. Next-Generation Sequencing (NGS)
• 7.3. Polymerase Chain Reaction (PCR)

8. Next-Generation Gynecological Cancer Diagnostics Market, by Indication

• 8.1. Introduction
• 8.2. Cervical Cancer
• 8.3. Ovarian Cancer
• 8.4. Uterine Cancer

9. Next-Generation Gynecological Cancer Diagnostics Market, by End User

• 9.1. Introduction
• 9.2. Academic & Research Institutes
• 9.3. Diagnostic Laboratories
• 9.4. Hospitals & Ambulatory Centers

10. Americas Next-Generation Gynecological Cancer Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. ARUP Laboratories
• 4. Becton, Dickinson and Company
• 5. BGI Genomics Co., Ltd.
• 6. Bio-Rad Laboratories, Inc.
• 7. Centogene N.V.
• 8. Danaher Corporation
• 9. Epic Sciences Inc.
• 10. Exact Sciences Corporation
• 11. F. Hoffmann-La Roche Ltd.
• 12. Fujifilm Holdings Corporation
• 13. Fulgent Genetics, Inc.
• 14. GE HealthCare Technologies, Inc.
• 15. Hologic, Inc.
• 16. Illumina, Inc.
• 17. Interpace Diagnostics, LLC
• 18. Janssen Pharmaceuticals, Inc.
• 19. Konica Minolta, Inc.
• 20. Koninklijke Philips N.V.
• 21. Lucence Diagnostics Pte Ltd
• 22. Medtronic plc
• 23. Merck KGaA
• 24. Myriad Genetics, Inc.
• 25. Natera, Inc.
• 26. Novartis AG
• 27. QIAGEN N.V.
• 28. Siemens Healthineers AG
• 29. Thermo Fisher Scientific Inc.